A new interactive conference will address key strategies for the commercialization of emerging medical technologies, and its unique format will have you on the edge of your seat.
The event brings together a star-studded lineup of those who have done it — and done it well. These industry leaders detail the critical steps necessary to get emerging products to market, including talking about the often-difficult task of finding the necessary financial resources to make this pathway feasible. The event takes place June 25, 2018, at the Westin Waltham in Boston.
MedInnovation Boston 2018 kicks off with a keynote presentation from John McDonough, president and CEO of T2Biosystems, a company developing innovative applications of proven technology in a space of high unmet need. He tells what he believes industry must do in emerging medtech for successful product commercialization, sharing the background of his company’s organizational focus on healthcare diagnostics and his approach for choosing commercial targets.
The morning sessions will feature three additional success stories: leaders from MC10, Inc., Sterilis Medical, Inc., and Corvida Medial will delve into how they’ve been able to bring paradigm shifting products to market. These sessions present real, actionable models and offer tips to ensure success. Ben Schlatka, co-founder of MC10 will discuss how the company augmented its novel technology with a complete end-to-end system that includes mobile interfaces, cloud storage, and analytical tools to create a high barrier to competitors. Mike Ferris, SVP of marketing for Sterilis will share insights on how to identify overlooked market niches in a commoditized world, while the co-founder of Corvida, John Slump, will share how his company created its competitive advantage.
But what about funding? It is such a critical component of commercializing innovative emerging technologies. The afternoon sessions will dive into this aspect with keynote presentations from industry experts who have found creative ways to fund their companies. Jeffrey Burbank, CEO and founder of NxStage Medical will talk about how he started his company from scratch in 1998. Paul Gudonis, chairman and CEO of Myomo, will discuss the timeline, costs, advantages, and disadvantages of going public via the JOBS Act/Regulation A+ process.
Afternoon breakout sessions will explore the advances that are driving emerging technologies — from genomics to virtual hospitals, the IoT, 3D printing, and much more. Sam Onukuri, senior fellow and head of Johnson & Johnson’s 3D Center of Excellence will be on hand to discuss recent innovations in 3D printing and what to expect in the near future.
So, if it’s time for you to make your mark, this event is designed for you.
Sherrie Trigg
Editor and Director of Medical Content
To learn more and to register for the event, go to www.medinnovationevent.com .